Document is current
Any future updates will be listed below
-
Authors
Kashihara, Naoki
Kumeda, Yasuro
Higashino, Yorihiko
Maeda, Yoshitaka
Kaneko, Yoko
Kanai, Hidetoshi
Taniguchi, Yuko
Ishii, Takayuki
Tomioka, Yusuke https://orcid.org/0009-0004-4165-8121
-
Funding
Funding for this research was provided by:
AstraZeneca
Gilead Sciences
Kyowa Kirin
GlaxoSmithKline Japan
Daiichi-Sankyo
Takeda Pharmaceutical Company
Astellas Pharma
Otsuka Pharmaceutical
Mitsubishi Tanabe Pharma Corporation
Toray Industries
Baxter
Chugai Pharmaceutical
Bayer Yakuhin
Ono Pharmaceutical
Boehringer Ingelheim Japan
Zeria Pharmaceutical
- License Information
-
More Information
Article History
Received: 18 September 2024
Accepted: 25 October 2024
First Online: 24 November 2024
Declarations
:
: N Kashihara has received consulting fees from AstraZeneca, Gilead Sciences, Kyowa Kirin, and GlaxoSmithKline, and has received honoraria for lectures from Daiichi Sankyo, Takeda Pharmaceutical, Astellas Pharma, Otsuka Pharmaceutical, and Kyowa Kirin, and has received research grants from Mitsubishi Tanabe Pharma, Toray Industries, Baxter, Chugai Pharmaceutical, Kyowa Kirin, Bayer Yakuhin, Ono Pharmaceutical, Daiichi Sankyo, Nippon Boehringer Ingelheim, Astellas Pharma, and Takeda Pharmaceutical. Y Kumeda, Y Higashino, Y Maeda, Y Kaneko and H Kanai have no conflicts of interest to declare. Y Taniguchi, T Ishii and Y Tomioka are employees of Zeria Pharmaceuticals.
